Brokerages Set $1.50 Price Target for Cesca Therapeutics Inc (KOOL)

Shares of Cesca Therapeutics Inc (NASDAQ:KOOL) have earned an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Analysts have set a 1 year consensus price target of $1.50 for the company and are expecting that the company will post ($0.10) EPS for the current quarter, according to Zacks. Zacks has also given Cesca Therapeutics an industry rank of 88 out of 257 based on the ratings given to its competitors.

Separately, Zacks Investment Research lowered shares of Cesca Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 18th.

Shares of NASDAQ KOOL traded down $0.02 during mid-day trading on Monday, reaching $0.27. The company had a trading volume of 143,387 shares, compared to its average volume of 427,748. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.93 and a quick ratio of 0.97. The firm has a market capitalization of $6.29 million, a price-to-earnings ratio of -0.28 and a beta of -0.68. Cesca Therapeutics has a 12-month low of $0.22 and a 12-month high of $4.14.

Cesca Therapeutics (NASDAQ:KOOL) last posted its quarterly earnings results on Monday, August 13th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.16. The business had revenue of $2.00 million during the quarter, compared to analyst estimates of $3.00 million. Cesca Therapeutics had a negative net margin of 322.75% and a negative return on equity of 18.05%. On average, analysts predict that Cesca Therapeutics will post 0.1 EPS for the current year.

About Cesca Therapeutics

Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.

Further Reading: Technical Analysis

Get a free copy of the Zacks research report on Cesca Therapeutics (KOOL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit